Estiar_2017_Future.Oncol_13_961

Reference

Title : Clinical significance of NDRG3 in patients with breast cancer - Estiar_2017_Future.Oncol_13_961
Author(s) : Estiar MA , Zare AA , Esmaeili R , Farahmand L , Fazilaty H , Jafari D , Samadi T , Majidzadeh AK
Ref : Future Oncol , 13 :961 , 2017
Abstract :

AIM: The expression level of NDRG3 gene is investigated among breast cancer (BC) patients. METHODS: Real-time quantitative PCR was performed. RESULTS: NDRG3 was downregulated in BC patients particularly in advanced stage of the disease. HER2 status was significantly correlated with the expression of NDRG3. Also, triple-negative BC patients showed low levels of NDRG3 expression in comparison to other subtypes. Lastly, the expression of NDRG3 had significant impact on survival, with NDRG3 downregulated patients having the worst event-free survival rate among others. CONCLUSION: We have presented that NDRG3 might be a tumor suppressor candidate. NDRG3 downregulation might be involved in the tumorigenesis and development of invasive BC in an advanced phase of the disease.

PubMedSearch : Estiar_2017_Future.Oncol_13_961
PubMedID: 28326836

Related information

Citations formats

Estiar MA, Zare AA, Esmaeili R, Farahmand L, Fazilaty H, Jafari D, Samadi T, Majidzadeh AK (2017)
Clinical significance of NDRG3 in patients with breast cancer
Future Oncol 13 :961

Estiar MA, Zare AA, Esmaeili R, Farahmand L, Fazilaty H, Jafari D, Samadi T, Majidzadeh AK (2017)
Future Oncol 13 :961